Ascendis Pharma A/S
260.81USD
-9.2800 (-3.44%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.95▼ | $1.2 | 0 | 2 |
| Next quarter | $1.18▼ | $1.75 | 0 | 2 |
| Current year | $11.29▼ | $12.01 | 0 | 2 |
| Next year | $8.05▼ | $9.15 | 1 | 1 |
Beat in 2 of the last 2
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.77 | $0.9 | +0.13 (+17.4%) |
| 2026-03-31 | $-0.08 | $0.27 | +0.35 (+429.3%) |
231 ratings from 25 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Oppenheimer | Maintained | Outperform | $304 $312 | Sep 2, 2026 |
| Morgan Stanley | Maintained | Overweight | $275 $273 | Sep 1, 2026 |
| Wedbush | Reiterated | Outperform | $327 | Sep 1, 2026 |
| B of A Securities | Maintained | Buy | $306 $304 | Aug 31, 2026 |
| Jefferies | Maintained | Buy | $333 $330 | Aug 31, 2026 |
| Stifel | Maintained | Buy | $328 $326 | Aug 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $345 $344 | Aug 31, 2026 |
| HC Wainwright & Co. | Initiated | Buy | $345 | Aug 27, 2026 |
| BMO Capital | Initiated | Outperform | $319 | Aug 19, 2026 |
| TD Cowen | Maintained | Buy | $325 $341 | Aug 14, 2026 |
| RBC Capital | Maintained | Outperform | $280 $290 | Aug 14, 2026 |
| Barclays | Maintained | Overweight | $345 $329 | Aug 14, 2026 |
| Morgan Stanley | Maintained | Overweight | $256 $275 | Jul 23, 2026 |
| RBC Capital | Maintained | Outperform | $275 $280 | Jul 7, 2026 |
| Citigroup | Initiated | Buy | $355 | May 19, 2026 |
| Evercore ISI Group | Maintained | Outperform | $324 $329 | May 15, 2026 |
| Barclays | Maintained | Overweight | $342 $345 | May 11, 2026 |
| Wells Fargo | Maintained | Overweight | $330 $326 | May 8, 2026 |
| B of A Securities | Maintained | Buy | $262 $292 | Apr 16, 2026 |
| Wedbush | Reiterated | Outperform | $273 | Apr 9, 2026 |
| RBC Capital | Maintained | Outperform | $250 $275 | Mar 3, 2026 |
| Oppenheimer | Maintained | Outperform | $246 $262 | Feb 12, 2026 |
| Wedbush | Maintained | Outperform | $240 $273 | Feb 12, 2026 |
| B of A Securities | Maintained | Buy | $246 $260 | Jan 30, 2026 |
| Barclays | Initiated | Overweight | $342 | Jan 28, 2026 |
10 filings from 5 insiders · 5 buy / 2 sell over 6m
Officers and directors of ASND, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bodenhoff MadsOfficer, SVP & PAO | ExerciseWarrants | 3.0k | — | — | Sep 8, 2026 |
| Bodenhoff MadsOfficer, SVP & PAO | Sell | 3.0k | $270.19 | $811k | Sep 8, 2026 |
| Bodenhoff MadsOfficer, SVP & PAO | Exercise | 3.0k | $110.00 | $330k | Sep 8, 2026 |
| HOLTUG LARSDirector | Sell | 236 | $264.13 | $62k | Sep 2, 2026 |
| BIENAIME JEAN-JACQUESDirector | Buy | 2.0k | $245.85 | $493k | Aug 14, 2026 |
| SMITH SCOTT THOMASChief Financial Officer | Buy | 100 | $219.00 | $22k | Jun 2, 2026 |
| BIENAIME JEAN-JACQUESDirector | Buy | 500 | $222.30 | $112k | May 29, 2026 |
| SMITH SCOTT THOMASChief Financial Officer | Buy | 250 | $223.32 | $56k | May 29, 2026 |
| BIENAIME JEAN-JACQUESDirector | Buy | 400 | $236.24 | $95k | May 26, 2026 |
| JENSEN FLEMMING STEENOfficer | Sell | 19.5k | $238.49 | $4.64M | May 11, 2026 |
No analyst notes on ASND yet.
Analyst Ratings
20 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 16 | 0 | 0 | 0 | Buy1.80 |
| 1 mo ago | 4 | 16 | 0 | 0 | 0 | Buy1.80 |
| 2 mo ago | 4 | 14 | 0 | 0 | 0 | Buy1.78 |
| 3 mo ago | 4 | 14 | 0 | 0 | 0 | Buy1.78 |